Radio and PodcastRadio and PodcastLive Radio & Podcasts
BCL2 & HER2 Targeting Agent Updates artwork
Science & Medicine

BCL2 & HER2 Targeting Agent Updates

OncoPharm by OncoPharmPod

May 21, 202600:13:45Science & Medicine

The FDA has been a bunch of busy bees with new approvals: 1. Sonrotoclax, an exciting new BCL2 inhibitor approved for 3rd-line Mantle Cell Lymphoma 2. An all PO regimen of decitabine/cedazuridine + venetoclax is approved...

Related Episodes

Continue listening to more episodes from OncoPharm.

Lirafugratinib + LITESPARK011

Oct 1, 2026 - 00:15:34

This week's pod offers a brief review of FGFR inhibitors for cholangiocarcinoma in repsonse to the FDA ap...

PI3K Pathway Hyperglycemia

Sep 24, 2026 - 00:10:07

Drugs that inhibit signaling via the PI3K pathway (e.g. alpelisib, capivasertib) can cause hyperglycemia....

Paradigm and Daraxonrasib in NSCLC

Sep 3, 2026 - 00:14:31

PARADIGM is finally published, so we have more details from this study presented at ASH about HMA/Ven vs....

Iberdomide

Aug 20, 2026 - 00:15:37

CELMoDs are here, but are they here to stay? CELMoD/IMiD review article: Download the Oncology Learning C...